Cellegy's stock price dropped by 39% to $3.18 due to a clinical hold by the FDA on the company's drug candidate.
Cellegy's stock price dropped significantly on the Nasdaq Stock Market due to unknown reasons, causing shares to plunge to $3.23 from $1.99.